Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Q1 2025 revenue€ 1,068 million Group revenue, in line with expectations New leadership in motion to put the company back on-track to return to robust growth and free cash flow generation First...
-
Nilörngruppen AB today published the Annual Report and the Sustainability Report for 2024 on the company's website, www.nilorn.se. We have chosen to integrate sustainability reporting into our annual...
-
New York City, April 23, 2025 (GLOBE NEWSWIRE) -- Introduction What Is Superconductor Slim? Superconductor Slim is a premium liquid metabolism booster designed to support efficient fat burning,...
-
WABASH, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- FFW Corporation (the “Corporation”) (OTC PINK: FFWC) (4/22/2025 Close: $39.70), parent corporation of Crossroads Bank (the “Bank”), announced...
-
BOCA RATON, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Kindcard, Inc. (OTC Markets: KCRD) (“Kindcard” and the “Company”), an innovative FinTech and PayTech company which provides alternative payments...
-
Innofactor Plc | Stock Exchange Release | April 23, 2025 at 18:00 EEST The arbitral tribunal has confirmed Onni Bidco Oy’s redemption right over the minority shares in Innofactor Plc, and trading in...
-
- The U.S. Securities and Exchange Commission (“SEC”) has declared effective the post-effective amendment to the registration statement on Form F-4 (File No. 333-283650) (as amended, the “Registration...
-
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq:...
-
MAHWAH, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Radware® (NASDAQ: RDWR), a global leader in application security and delivery solutions for multi-cloud environments, today released its “2025...
-
- Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma...